(NASDAQ: ADVM) Adverum Biotechnologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Adverum Biotechnologies's earnings in 2025 is -$153,159,000.On average, 4 Wall Street analysts forecast ADVM's earnings for 2025 to be -$128,269,101, with the lowest ADVM earnings forecast at -$171,304,011, and the highest ADVM earnings forecast at -$73,953,195. On average, 4 Wall Street analysts forecast ADVM's earnings for 2026 to be -$81,578,312, with the lowest ADVM earnings forecast at -$147,279,668, and the highest ADVM earnings forecast at -$42,826,003.
In 2027, ADVM is forecast to generate -$87,949,986 in earnings, with the lowest earnings forecast at -$87,949,986 and the highest earnings forecast at -$87,949,986.